New cephalosporins in development pipelines

References

• APPLEBAUM PC: Antimicrobial resistance inStreptococ-cuspneumoniae: an overview. Clinical Infectious Diseases (1992) 15:77–83.
   PubMed Web of Science ®Google Scholar
• SANDERS CC, SANDERS WEJ: 13-lactam resistance in Gram-negative bacteria: global trends and clinical im-pact. Clinical Infectious Diseases (1992) 15:824-839. Excellent review of the impact of fl-lactamases on cell-wall inhibitors.
   Google Scholar
• MURRAY BE: P-lactamase producing enterococci. An-timicrob. Agents Chemother. (1992) 36:2355–2359.
   PubMed Web of Science ®Google Scholar
• GRLINEBERG RN: Changes in the antibiotic sensitivities of urinary pathogens 1971-1989. J. Antimicrob. Chemother. (1990) 26:3–11.
   PubMed Web of Science ®Google Scholar
• COLLATZ E, LABIA R, GUTMANN L: Molecular evolution seof ubiquitous beta-lactamases towards extended-spec-trum enzymes against newer beta-lactam antibiotics. Mol. Micn9biol. (1990) 4:1615–1620.
   PubMed Web of Science ®Google Scholar
• Excellent reivew of the impact of 13-lactamases on cell-wall inhibitors.
   Google Scholar
• CULLMANN W: The threat of resistance to the new oral cephalosporins. Chemotherapy (1992) 38:10–17.
   PubMed Web of Science ®Google Scholar
• KITZIS MD, LIASSINE N, FERRÉ B, GUTMANN L, ACAR JF, GOLDSTEIN F: in vitro activities of 15 oral 13-lactams against Kiebsiella pneumoniae harboring new ex-tended spectrum 0-lactamases. Antimicrob. Agents Chemother. (1990) 34:1783–1786.
   PubMed Web of Science ®Google Scholar
• Good comparison of different susceptibilities to 13-lactamases.
   Google Scholar
• NISHIMURA K, YOSHIMI A, KITAGAWA M, HASHIZUME H, MURO H, KASAI M, HATANO S, KAKEYA N: KY-020, anew sweet tasting and orally absorbed pro-drug of cefti-zoxime; oral absorption and efficacy in animals. 30th Interscience Conference on Antimicrobial Agents and Che-motherapy Atlanta (1990) Abstr. 674.
   Google Scholar
• KOBORI T, FUJITA M, YAMAMOTO R, HIYAMA T, KONDO K, NUMATA K. NAGATE T, HANADA K: SC-002, a new cephalosporin: synthesis and in vitro antibacterial ac-tivity. 32nd Interscience Conference on Antimicn9bialAgents and Chemotherapy Anaheim (1992) Abstr. 190.
   Google Scholar
• NUMATA K, SUGITA K, AKASHI T, KANEDA Y, NAGATE T, FIANADA K: SC-004, a new oral cephalosporin: In vivo antibacterial activity and oral absorption. 32nd Inter-science Conference on Antimicrobial Agents and Chemother-apy Anaheim (1992) Abstr. 191.
   Google Scholar
• SAKAGAMI K, ATSUMI K, TAMURA A, YOSHIDA T, NISHI-HATA K, FUKATSU S: Synthesis and oral activity of ME 1207, a new orally active cephalosporin. J. Antibiot. (1990) 43:1047–1050.
   PubMed Web of Science ®Google Scholar
• SAKAGAMI K, ATSUMI K, YAMAMOTO Y, TAMURA A, YOSHIDA T, NISHIHATA K, FUKATSU S: Synthesis and oral activity of pivaloyloxyraethyl 7-[(Z)-2-(2-ami-nothiazol-4-y1)-2-methoxylminoacetamido]-3(Z)-(4-m ethylthiazol-5-yOvinyl-3-cephem-4-carboxylate (ME 1207) and its related compound. Chemical Pharmaceuti-cal Bulletin (1991) 39:2433–2436.
   PubMedGoogle Scholar
• TAMURA A, OKAIVIOTO R, YOSHIDA T, YAMAMOTO H,KONDO S, INOUYE M, MITSUHASHI S: In vitro and in vivo antibacterial activities of ME-1207, a new cepha-losporin. Antimicrob. Agents Chemother. (1988) 32:1421–1426.
   PubMed Web of Science ®Google Scholar
• KANEKO A, SASAKI J, MORISHIMA T: Bacteriologicalevaluation of organisms isolated from a collaborative clinical study of cefditoren pivoxil (ME-1207). Oral Ther. Pharmacol. (1992) 11:124.
   Google Scholar
• SHIBA K, MAEZAWA H, YOSHIDA M: Comparative clinicalstudy of cefditoren pivoxil and cefteram pivoxil for bacterial pneumonia by a double-blind method. Chemo-therapy (Tokoyo) (1992) 40:1472.
   Google Scholar
• INOUE M, TAMURA A, YOSHIDA T, OKAMOTO R, ATSUMI K, NISHIHATA K, MITUHASHI S: A novel cephalosporin, ME-1207 - in vitro and in vivo activities. 25th Interscience Conference on Antimicrobial Agents and Chemotherapy Min-neapolis (1985) Abstr. 582.
   Google Scholar
• KOMIYA I, YOSHIDA T, MATSUMOTO T, YAMAMOTO Y,SAKAGAMI K, ATSUMI K, NISHIO M, KAZUNO Y, FUKATSU S, MITSUHASHI S: A novel cephalosporin, ME-1207 - pharmacoldnetic properties. 25th Interscience Confer-ence on Antimicrobial Agents and Chemotherapy Minneapo-lis (1985) Abstr. 583.
   Google Scholar
• TASHIRO M, MAGOME E, MIKI S, SAKAGAMI K: Inclusion complex of a new orally active cephalosporin ME-1207 with 13-cyclodextrin. Chem. Pharm. Bull. (1992) 40:1623–1625.
   Web of Science ®Google Scholar
• FUJIE R, YOSHIOKA H, OKUNO A, FUJITA K, MURONO K, SAKATA SMH, ISEKI K, WAGATSUMA Y et al.: Pharmacok-inetic and clinical studies of cefditoren pivoydl in the pediatric field. Jpn. J. Antibiot. (1993) 46:95–114.
   PubMedGoogle Scholar
• FUJII R, NISHIMURA T, SUNAKAWA K: Cefditoren pivoxil (CDTR-PD: pharmacokinetics. Influence on carnitine metabolism and clinical evaluation in pediatric pa-tients. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans (1993) Abstr. 897.
   Google Scholar
• NAKASHIMA M, MATSUNO S, YOSHIDA T, IUMURA Y, OGUMA T, ISHII H: Pharmacokinetics and safety of S-1108 in healthy vohmteers. 29th Interscience Conference on Antimicrobial Agents and Chemotherapy Houston (1989) Abstr. 370.
   Google Scholar
• SHIMIZU K, SAITO A, YAMAMATO S: Carnitine status and safety of S-1108, a new oral cephem, in patients. 32nd Interscience Conference on Antimicrobial Agents and Che-motherapy Anaheim (1992) Abstr. 185.
   Google Scholar
• KATO N, KATO H, TANAKA Y, BANDOH K, WATANABE K, UENO K: The in vitro activity of S-1006, the active form of a new oral cephalosporin, S-1108, against anaerobic bacteria. Chemotherapy (Tokyo) (1993) 41:40–49.
   Google Scholar
• YOSHIDA T, HAMASHIMA Y, KOMATSU Y, NOMURA K: S-1108, new oral cephem: antibacterial activity. 29th Interscience Conference on Antimicrobial Agents and Che-motherapy Houston (1989) Abstr. 368.
   Google Scholar
• MATSUURA S, YAMANO Y, NAKASHIMIZU H, MATSUBARA T, KOBAYASHI F, KUWAHARA S: S-1108, a new oral cephem: absorption and efficacy. 29th Interscience Con-ference on Antimicrobial Agents and Chemotherapy Houston (1985) Abstr. 369.
   Google Scholar
• SHIMIZU K, SAITO A, SHIMADA J: Carnitine status and safety after administration of S-1108, a new oral cephem, to patients. Antimicrob. Agents Chemother. (1993) 37:1043–1049.
   PubMed Web of Science ®Google Scholar
• FUJII R, SUNAKAWA K, YAMAMOTO 5: Carnitine status of S-1108 in pediatric patients with various infectious diseases. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy Anaheim (1992) Abstr. 186.
   Google Scholar
• JONES RN, ERWIN ME, BARRETT MS, BRIGGS BM, JOHNSON DM: In vitro activity of RU-29246: the meta-bolite of a new HR-916 cephalosporin ester. Diagn. Micro biol. Infect. Dis. (1991) 14:473–483.
   PubMed Web of Science ®Google Scholar
• DEFOSSA E, DURCKHEIMER W, FISCHER G, JENDRALLA FI, KLESEL N, WOLLMANN T: Cefdaloxime pentexil tosilate (HR916 K) - a diastereomerically pure novel oral cepha-losporinester: synthesis and antibacterial acitivity in vivo. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy Anaheim (1992) Abstr. 187.
   Google Scholar
• ISERT D, FISCHER G, KLESEL N, LIMBERT M, MARKUS A, RIESS G, SEIBERT G: Cefdaloxime pentexil tosilate (III(916 K): a diastereomerically pure novel oral cepha-losporinester with outstanding absorption charac-teristics. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy Anaheim (1992) Abstr. 188.
   Google Scholar
• MENDES P, MEYER BH, MULLER FO, SCHOLL T, LUUS H, DE LA REY N: Pharniacokinetics of cefdaloxirne pentexil tosilate (111(916 K) after a single oral dose in healthy volunteers. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy Anaheim (1992) Abstr. 189.
   Google Scholar
• ANGEHRN P, HOHL P, FIUBSCHWERLEN C, PAGE M, THENR: Antibacterial properties of Ro 40-6890, a broad-spec-trum cephalosporin, and its novel orally absorbable ester, Ro 41-3399. Antimicrob. Agents Chemother. (1992) 36:2825–2834.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, BARRY AL, FUCHS PC: Antimicrobial activ-ity and disk diffusion susceptibility testing of Ro 40-6890, the active metabolite of the new cephalosporin ester, Ro 41-3399. Antimicrob. Agents Chemother. (1993) 37:893–895.
   PubMed Web of Science ®Google Scholar
• WOST J, HARDEGGER U: Comparative in vitro activity ofRo 40-6890, Ro 41-3399 and other antimicrobial agents against anaerobic bacteria. Eur. J. Clin. Microbiol. Infect. Dis. (1992) 11:946–949.
   PubMed Web of Science ®Google Scholar
• JONES RN, BARRY L, THE COLLABORATIVE ANTIMICRO-BIAL SUSCEPTIBILITY TESTING GROUP: Ceftibuten (7432-S, SCH-39720): comparative antimicrobial activity against 4735 clinical isolates. 111-lactantase stability and broth microdilution quality control guidleines. Eur. J. Clin. Infect. Dis. (1988) 7:802.
   PubMed Web of Science ®Google Scholar
• WISE R, ANDREWS JM, ASHBY JP, THORNBEN D: Ceftib-uten - in vitro activity against respiratory pathogens, P-lactamase stability and mechanism of action. I An-timicrobial Chemother. (1990) 26:209–213.
   PubMed Web of Science ®Google Scholar
• DEBBIA EA, PESCE A, CHIESA M, RICOTTA N, SCHITO GC:Microbiologic profile of ceftibuten, a new oral cepha-losporin. J. Antibiot. (1992) 18:129–139.
   Google Scholar
• MINE Y, KAMIMURA T, WATANABE Y, TAWARA S, MATSU-MOTO Y, SHIBAYAMA F, KIKUCHI TAKAYA T, KUWA-HARA S: In vitro antibacterial activity of FK482, a new orally active cephalosporin. J. Antibiot. (1988) 41:1873–1887.
   PubMed Web of Science ®Google Scholar
• MINE Y, YOKOTA Y, WAKAI Y, KAMIMURA T, TAWARA S,SHIBAYAMA F, KIKUCHI H, KUWAHARA S: In vivo an-tibacterial activity of FK482, a new orally active cepha-losporin. J. Antibiot. (1988) 41:1888–1895.
   PubMedGoogle Scholar
• QADRI SMH, UENO Y, SALDIN H, CUNHA BA: In vitroactivity of cefdinir (FK 482, PD 134393, CI-983): a new orally active cephalosporin. Chemotherapy (1993) 39:112–119.
   PubMed Web of Science ®Google Scholar
• NEU HC, SAHA G, CHIN NX: Comparative in vitro activityand 13-lactamase stability of FK482: a new oral cepha-losporin. Antimicrob. Agents Chemother. (1989) 33:1795–1800.
   PubMed Web of Science ®Google Scholar
• INAMOTO Y, CHIBA T, KAMIMURA T, TOKAYA T: FK 482,a new orally active cephalosporin: synthesis and bio-logical properties. J. Antibiotics (1988) 41:828–830.
   PubMed Web of Science ®Google Scholar
• JOHNSON DM, JONES RN: Antibacterial activity of the Investigational oral and parenteral cephalosporin BK-218. Eur. J. Clin. Microbial. Infect. Dis. (1992) 11:181–188.
   PubMed Web of Science ®Google Scholar
• SZABO I, BARABAS J, TAR A, KISS L, FILEP M, SCHMIDT T, MAROSSY K, TOTH-MARTINEZ B, BARABAS G, HERNADI F: In vitro investigation of BK-218, a new oral and parenteral cephalosporin. Antimic rob. Agents Chemother. (1990) 34:349–354.
   PubMed Web of Science ®Google Scholar
• TSUSHIMA M, TAMURA A, HARA T, IWAMATSU K, SHIBA-HARA S: Synthesis and biological properties of CP0467, a new cephem possessing excellent activity against MRSA. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy Anaheim (1992) Abstr. 394.
   Google Scholar
• MURAKAMI K, KUBOTA T, SASAKI S, MIWA H, KIMURA Y, KOMATSU Y, YOSHIDA T: S-1090, a new oral cepha-losporin; L Antibacterial activity. 32nd Interscience Con-ference on Antimicrobial Agents and Chemotherapy Anaheim (1992) Abstr. 183.
   Google Scholar
• KIMURA Y, NAKASHIMIZU H, MURAKAMI K, KOIKE M, NISHIUCHI M: S-1090, a new oral cephalosporin: phannacnkinetics in animals 32nd Interscience Confer-ence on Antimicrobial Agents and Chemotherapy Anaheim (1992) Abstr. 184.
   Google Scholar
• NAKASHIMA M, IMOTO H, KIMURA Y, SASAKI S, OGUMAT, YAMAMATO S: S-1090, a new oral cephem antibiotic pharmacokinetics in humans. 33rd lnterscience Confer-ence on Antimicrobial Agents and Chemotherapy New Or-leans (1993) Abstr. 416.
   Google Scholar
• INAMOTO Y, GOTO J, SAKANE K, KAMIMURA T, TAKAYAT: Studies on13-lactam antibiotics /CM Structure-activity relationships of cephalosporirts having a thiadia-zolylthiomethyl group at the C-3 side chain- J. Antibiot. (1991) 44:507–516.
   Google Scholar
• ASADA K, SUZUKI E, KONDO N, KUWUHARA-ARAI K, HIRAMITSU K: In vitro antimicrobial activity of a newly synthesized oral cephem antibiotic, E1101. 33rd Inter-science Conference on Antimicrobial Agents and Chemother-apy New Orleans (1993) Abstr. 893.
   Google Scholar
• NEGI S, YAMANAKA M, SUGIYAMA I, KOMATSU Y, SASHO M, TSURUOKA A, KAMADA A, TSUKADA I, HIRUMA R, KATSU K et al.: E1101, a new oral cephalosporin: L Synthesis and structure activity relationships of 3-sub-stitued carcamoyloxymethyl cephems. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans (1993) Abstr. 894.
   Google Scholar
• HIRUMA R, UENO J, MORIYAMA M, NEGI S, KATSU K:E1101, a new oral cephalosporin: IL In vitro antibacte-rial activity. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans (1993) Abstr. 895.
   Google Scholar
• HIRUMA R, MORIYAMA M, UENO J, TOYOSAWA T, HATA K, UEMURA Y, KATSU K: E1101, a new oral cepha-losporin: /IL In vivo antibacterial activity. 33rd Inter-science Conference on Antimicrobial Agents and Chemotherapy New Orleans (1993) Abstr. 896.
   Google Scholar
• SAKAGAMI K, IWAMATSU K, ATSUMI K, HATANAKA M: Synthetic cephalosporins VIII. Synthesis and antibacte-rial activity of CP6232, a new antipseudomonal cepha-losporin. I Antibiot. (1992) 45:595–598.
   Google Scholar
• BERGAN T, DA FONSECA J: Efficacy of cefcanel on staphlococci. Chemotherapy (1991) 37:43–49.
   PubMed Web of Science ®Google Scholar
• BERGAN T, DA FONSECA J: Antibacterial activity of cefcaneL Chemotherapy (1993) 39:96–104.
   Google Scholar
• NORD CE, LINDMARK A, PERSSON I: Comparative an- tibacterial activity of the new cephalosporin cefcanel against anaerobic bacteria. Eur. j Clin. Micro biol. Infect. Dis. (1989) 8:550–556.
   PubMed Web of Science ®Google Scholar
• CHIN NX, GU JW, NEU HC: In vitro activity of cefcanel versus other oral cephalosporins. Eur. J. Clin. Microbiol.Infect. Dis. (1991) 10:676–682.
   PubMed Web of Science ®Google Scholar
• Good comparison of cephalosporins in vitro.
   Google Scholar
• MIKAMO H, TAMAYA T, HACHIYA S, SATOH M: Effects of a novel cephalosporin E1077 on intrauterine infections In a newly designed rat modeL 33rd Interscience Confer-ence on Antimicrobial Agents and Chemotherapy New Or-leans (1993) Abstr. 869.
   Google Scholar
• TAKUMA K, AIKAWA N, SHINOZAWA Y, HORI S, SASAKI J, HACHIYA S, SATOH M: Mechanism of elevated levels of E1077, a new cephalosporin, in burned rat eschar. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans (1993) Abstr. 870.
   Google Scholar
• SATOH M, TAKEUCHI H, YOSHIDA 0: Prominent effects of a newer injectable cephalosporin, E1077 on the experimental refractory complicated UTI caused by E. faecalis and P. aeruginosa in rats. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans (1993) Abstr. 871.
   Google Scholar
• PAULFEUERBORN W, MULLER H-J, BORNER K, KOEPPE P, LODE H: Comparative pharmacokinetics and serum bactericidal activities of SCE-2787 and ceftazidime. An-timicrob. Agents Chemother. (1993) 37:1835–1841.
   PubMed Web of Science ®Google Scholar
• IWAHI T, OKONOGI K, YAMAZAKI T, SHIKI S, KONDO M, MIYAKE A, IMADA A: In vitro and in vivo activities of SCE-2787, a new parenteral cephalosporin with broad antibacterial spectrum. Antimicrob. Agents Chemother. (1992) 36:1358–1366.
   PubMed Web of Science ®Google Scholar
• IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI T, YAMAZAKI T, IMADA A: Therapeutic effect of cefozopran (SCE-2787), a new parenteral cephalosporin, against experi-mental infections in mice. Antimicrob. Agents Chemother. (1993) 37:100–105.
   PubMed Web of Science ®Google Scholar
• WATANABE NA, HIRUMA R, KATSU K: Comparative in vitro activities of newer cephalosporins cefclidin, ce-fepime and cefpirome against ceftazidime or imipenem-resistant Pseudomonas aeruginosa. J. An-timicrob. Chemother. (1992) 30:633–641.
   PubMed Web of Science ®Google Scholar
• HARA K, KOHNO S, KOGA H, SAITO A, OHMICHI M, HIRAGA Y, TAICEBE K, YOSHIDA T, ITO T, WATANABE K et al.: A comparative study of cefclidin and ceftazidime In chronic respiratory tract infections. Chemotherapy (Tokyo) (1993) 41:104–127.
   Google Scholar
• HARA K, KOHNO S, KOGA H, OE T, KATSUMATA T, ASAI S, MASHIMOTO Fl, SUYAMA T, WATANABE K, IRIFUNE K et al.: A comparative study of cefclidin and ceftazidime in bacterial pneumonia. Chemotherapy (Tokyo) (1993) 41:78–103.
   Google Scholar
• SAITO A, TOMIZAWA M, NAKAYAMA I, SATO K: Basic andclinical studies on cefclidin. Chemotherapy (Tokyo) (1992) 40:258–266.
   Google Scholar
• LIMBERT M, ISERT D, KLESEL N, MARKUS A, SEEGER K,SEIBERT G, SCHRINNER E: Antibacterial activities in vitro and in vivo and pharmacoldnetics of cefquinome (EIR 111V), a new broad-spectrum cephalosporin. Antimi-crob. Agents Chemother. (1991) 35:14–19.
   PubMed Web of Science ®Google Scholar
• CHIN NX, GU JW, FANG W, NEU HC: In vitro activity ofcefquinome, a new cephalosporin, compared with other cephalosporin antibiotics. Diagn. Microbiol. Infect. Dis. (1992) 15:331–337.
   PubMed Web of Science ®Google Scholar
• CHENG AFB, LING TKW, LAM AW, FUNG ICSC, WISER: Theantimicrobial activity and13-lactamase stability of cefpi-rome, a new fourth-generation cephalosporin in com-parison with other agents. J. Antimicrob. Chemother. (1993) 31:699–709.
   PubMed Web of Science ®Google Scholar
• NEU HC, SAHA G, CHIN NX: In vitro activity of ME1228,a new parenteral cephalosporin. Antimicrob. Agents Chernother. (1989) 33:1260–1267.
   PubMed Web of Science ®Google Scholar
• MIYAZAKI S, MIYAZAKI Y, TSUJI A, NISHIDA M, GOTO S:In vitro and in vivo studies of ME1228, a new parenteral cephalosporin with potent activity against Pseudo-monas aeruginosa. Antimicrob. Agents Chemother. (1991) 35:1245–1246.
   PubMed Web of Science ®Google Scholar
• MINE Y, WATANABE Y, SAKAMOTO H, HATANO K, KUNO K, HIGASHI Y, KAMIMURA T, MATSUMOTO Y, TAWARA 5, MATSUMOTO F, et al.: In vitro antibacterial activity of FK037, a novel parenteral broad-spectrum cepha-losporin. j Antibiot. (1993) 46:71–87.
   Google Scholar
• NEU HC, CHIN NX, HUANG HB: In vitro activity and 13-lactamase stability of FK-037, a parenteral cepha-losporin. Antimicrob Agents Chemother. (1993) 37:566–573.
   PubMed Web of Science ®Google Scholar
• FU ICP, FOLENO BD, LAFREDO SC, LOCOCO JM, ISAACSON DM: In vitro and in vivo antibacterial activities of FK037, a novel parenteral broad-spectrum cephalosporin. An-timicrob. Agents Chemotber. (1993) 37:301–307.
   PubMed Web of Science ®Google Scholar
• SAKANE K, KAWABATA K, INAMOTO Y, OKUDA S, KAMIMURA R, TAKAYA T: FK-518, a new parenteral anti-pseudomonal cephalosporin L Synthesis and structure-activity relationships of 3-aminopyra-zoliomethyl cephalospoins. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy Atlanta (1990) Abstr. 454.
   Google Scholar
• MINE Y, SAKAMOTO H, KAMIMURA T, WATANABE Y, MATSUMOTO Y: FK-518, a new parenteral antipseudo-monal cephalosporin IL In vitro antibacterial activity. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy Atlanta (1990) Abstr. 455.
   Google Scholar
• MINE Y, SAKAMOTO H, KAMIMURA T, WATANABE Y, TAWARA S, KUWAHARA S: FK-518, a new parenteral antipseudomonal cephalosporin M. In vivo antibacte-rial activity. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy Atlanta (1990) Abstr. 456.
   Google Scholar
• SAKAMOTO H, MINE Y, KAMIMURA T, HIROSE T, KUWA-HARA A: FK-518, a new parenteral antipseudomonal cephalosporin IV. Pharmacoldnetics in experimental animals. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy Atlanta (1990) Abstr. 457.
   Google Scholar
• SHIBAHARA S, OKONOGI T, YOSHIDA T, MURAI Y, ICUDOT, INOUYE S, KONDO S: A new aminothiazolylcepha-losporin having 1-carboxyethoycyimino group, ME1228. j Antibiot. (1990) 43:62–69.
   PubMedGoogle Scholar
• ASZODI J, BONNEFOY A, CHANTOT JF, FAVEAU P, D'AM-BRIERES SG, MAUVAIS P: Synthesis and antibacterial activity of a series of novel catechol-substitued vinylo-gous cephalosporins. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans (1993) Abstr. 890.
   Google Scholar
• CURTIS NAG, EISENSTADT RL, EAST SJ, CORNFORD RJ, WALKER LA, WHITE AJ: Iron-regulated outer membrane proteins of Escbericbia coli K-12 and mechanism of action of catechol-substituted cephalosporins. Antimi-crob. Agents Chemother. (1988) 32:1879–1886.
   PubMed Web of Science ®Google Scholar
• NIKAIDO H, ROSENBERG EY: Cir and Fiu proteins in the outer menbrane of Eschericia colt catalyze transport of monomeric catechols: study with beta-lactam antibiot-ics containing catechol and analogous groups. J. Bade-riot (1990) 172:1361–1367.
   Google Scholar
• SILLEY P, GRIFFITHS JW, MONSEY D, HARRIS AM: Mode of action of GR69153, a novel catechol-substituted cephalosporin, and its interaction with the ton B-de-pendent iron transport system. Antimicrob. Agents Chemother. (1990) 34:1806–1808.
   PubMed Web of Science ®Google Scholar
• KAMACHI H, OKA M, NARITA Y, IIMLTRA S, ABURAIU S, YAMASHITA H, TOMATSU K, OKUMURA J, NAITO T: Synthesis of a new series of cephalosporins having 3-substituted ammonio-l-propenyl group as the C-3 side chain. J. Antibiot. (1990) 43:533–543.
   PubMed Web of Science ®Google Scholar
• ASZODI J, BONNET A, CHANTOT J-F, COSTEROUSSE G, TEUTSCH G: Synthesis and antibacterial activity of iso-cephems. In: Recent Advances in the Chemistry of f3-Lactam Antibiotics: Bentley PH, Southgate R (Eds), The Royal Society of Chemistry, London, 1989 p350–364.
   Google Scholar
• JONES RN, ERWIN ME: In vitro evaluation of Ro 09-1227, a novel catechol-substituted cephalosporin. Antimicrob. Agents Chemother. (1992) 36:233–238.
   PubMed Web of Science ®Google Scholar
• MAEJIMA T, INOUE M, MITSUHASHI S: In vitro antibacte-rial activity of ICP-736, a new cephem antibiotic. Antimi-crob. Agents Chemother. (1991) 35:104–110.
   PubMed Web of Science ®Google Scholar
• GEORGOPAPADAKOU NH, ALBRECHT HA, BERTASSO A, MCCAFFREY C: Mode of action of Ro 25–0534, a 3'-tertiary amine-linked dual action cephalosporin. 33rd Inter-science Conference on Antinzicrobial Agents and Chemother-apy New Orleans (1993) Abstr. 1493.
   Google Scholar
• WHITE RE, DEMUTH TP JR, BERK JD, 11E 1 JEN RA, JAMI-ESON LA, KRAFT WG, MCOSKER CC, DAVIS BW, ROURKE FJ: Preparation and comparative antibacterial activity of quinolyl-cephem amines and carbamates. 33rd Inter-science Conference on Antimicrobial Agents and Chemother-apy New Orleans (1993) Abstr. 1491.
   Google Scholar
• MATSUMATO M, YOKOMI K, YASAMURA K, TUBOUCHI H,TSUJI K, TAMAOKA H, KIKUCHI H: In vitro and in vivo activities of OPC-20000, a novel parenteral broad spec-trum 2-oxa-isocephem antibiotic. 33rd Interscience Con-ference on Antimicrobial Agents and Chemotherapy New Orleans (1993) Abstr. 886.
   Google Scholar
• WU CYE, FLOKOWITSCH JE, ALBORN WEJ, TERNANSKYRJ, PRESTON DA: Mechanism of action of a series of 3-substituted-1-carbacephems against methicillin-res is-tant Staphylococcus aureus (MRSA). 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans (1993) Abstr. 111.
   Google Scholar
• ALBORN WEJ, FLOKOWITSCH JE, WU CYE, PRESTON DA, TERNANSKY RJ: Biological evaluation of a series of carbacephems showing broad-spectrum activity in-cluding methicllin-resistant Staphylococcus aureus (MRSA). 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans (1993) Abstr. 926.
   Google Scholar
• TERNANSKY RJ, DRAHEIM SE, PIKE AJ, BELL FW, WEST SJ, JORDAN CL, WU CYE, PRESTON DA, ALBORN W, KASHER JS et al.: Discovery and structure-activity relationship of a series of 1-carba-1-dethiacephems exhibiting activity against methicillin-resistant Staphylococcus aureus. Med. Chem. (1993) 36:1971–1976.
   Web of Science ®Google Scholar
• GU jW, CHIN pc, NEU ITC: In vitro activity of an oxy-cephem OPC 9-176 compared with its sulfur analogue and other P-lactams. Diagn. Microbiol. Infect. Dis. (1991) 14:135–140.
   PubMed Web of Science ®Google Scholar